[ad_1]
US President Donald Trump previously reported that he made capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc, the makers of two of the drugs he took as part of his Covid-19 treatment plan.
According to a 2017 financial disclosure form filed with the US Government Ethics Office, in June 2017, Trump realized a capital gain of US $ 50,001 (NZ $ 75,404) to US $ 100,000 for Regeneron Pharmaceuticals and of US $ 100,001 US dollars to one million US dollars for Gilead Sciences Inc. form notes information was as of April 15, 2017.
Trump’s subsequent disclosure forms, including his 2020 form signed on July 31, did not include Regeneron or Gilead.
Trump received a single 8-gram dose of Regeneron’s polyclonal antibody cocktail as a precaution, according to his physician Sean Conley. The antibody cocktail is in four late-stage clinical trials and its safety and efficacy have not been fully evaluated by any regulatory authority, the company said on its website.
READ MORE:
* Covid-19: Doctor Says Trump Is On The Move, But He’s Not ‘Out Of The Way’ Yet
* Covid-19: The next 48 hours are critical for the president of the United States, Donald Trump, after a period ‘very worrying’ in the attention of the coronavirus
* Coronavirus: WHO stops testing for hydroxychloroquine for safety reasons
* Coronavirus: Trump’s ‘revolutionary’ drug linked to increased risk of death, study finds
As part of Operation Warp Speed, New York State-based Regeneron won a $ 450 million federal contract in July to manufacture and supply the company’s REGN-COV2 antibody cocktail.
The New York Times reported Friday that Regeneron CEO Dr. Leonard S. Schleifer, a member of the Trump Golf Club in Westchester County, New York, said Trump’s medical staff contacted the company. to get permission to use the drug and the Food and Drug Administration cleared it.
“All we can say is that they asked to be able to use it, and we were pleased to accommodate them,” Schleifer told the Times, calling it a case of “compassionate use.” Trump is not the first patient to try the experimental treatment outside of the clinical trial using compassion.
DONALD TRUMP / TWITTER
US President Donald Trump in a video posted on Twitter at noon Sunday (NZT).
“When it comes to the president of the United States, of course, which obviously gets our attention,” Schleifer told the Times. Regeneron’s stock rose $ 19.20 a share in after-hours trading.
Trump is also taking Gilead’s remdesivir, which has been cleared for Covid-19 patients by the FDA under an emergency use declaration. The trials showed effectiveness in some circumstances.
Remdesivir received cautious endorsement in April from Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases at the National Institutes of Health, when it was announced as a new tool in the fight against the virus at a new presidential conference.
It was unclear Saturday if the president currently has any direct involvement in Regeneron and Gilead, but it appears he still has a stake in hydroxychloroquine, a drug that he repeatedly touted as a treatment for Covid-19 despite warnings about its effectiveness.
Trump’s latest financial disclosure form reports his family trusts’ investments in a Dodge & Cox mutual fund. A New York Times article in April said the fund’s largest stake is believed to be in Sanofi, the pharmaceutical company that is a major producer of hydroxychloroquine.
Hydroxychloroquine is an arthritis medication that can also be used as a preventive or treatment for malaria, a red blood cell infection transmitted by the bite of a mosquito, according to the Mayo Clinic.
-USA. Nowadays
